NASDAQ · SRZNHealthcareBiotechnology

Surrozen financials

$31.98+7.89%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
Revenue$3.5M$10.7M$0.00$12.5M$0.00
Gross profit$3.5M$10.7M$0.00$12.5M$0.00
Gross margin100.0%100.0%—100.0%—
Operating income-$42.1M-$25.5M-$45.8M-$44.3M-$54.4M
Net income-$242.0M-$63.6M-$43.0M-$36.0M-$54.6M
Net margin−6960.8%−596.6%—−288.0%—
Diluted EPS$-32.37$-21.67$-21.33$-15.56$-33.15
EBITDA-$41.6M-$24.1M-$41.1M-$42.4M-$52.2M
Operating cash flow-$30.2M-$17.6M-$40.4M-$44.1M-$48.8M
Free cash flow-$30.4M-$17.7M-$40.8M-$44.9M-$50.1M
Diluted shares7.5M2.9M2.0M2.3M1.6M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$89.2M$34.6M$36.0M$24.7M$33.1M
Short-term investments$0.00$0.00$0.00$51.1M$68.8M
Total debt$0.00$0.00$0.00$0.00$0.00
Total assets$98.7M$48.5M$46.1M$89.4M$137.2M
Total liabilities$286.5M$69.8M$8.1M$13.4M$27.5M
Shareholders' equity-$187.8M-$21.4M$37.9M$76.0M$109.7M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology